Long-term inhibition of mTOR by rapamycin or latrepirdine also prevents AD-like cognitive deficits and lowers Aβ42 level, reduces amyloid plaques and tau NFTs (McGowan et al., 2005; Caccamo et al., 2010; Spilman et al., 2010; Majumder et al., 2011). The gene discussed is MAPT; the disease is Alzheimer disease.